Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adagio Medical Holdings (ADGM) Other Accumulated Expenses (2023 - 2026)

Adagio Medical Holdings has reported Other Accumulated Expenses over the past 4 years, most recently at $360000.0 for Q1 2026.

  • Quarterly Other Accumulated Expenses rose 135.29% to $360000.0 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $360000.0 through Mar 2026, up 135.29% year-over-year, with the annual reading at $411000.0 for FY2025, 47.31% up from the prior year.
  • Other Accumulated Expenses was $360000.0 for Q1 2026 at Adagio Medical Holdings, down from $411000.0 in the prior quarter.
  • Over five years, Other Accumulated Expenses peaked at $513000.0 in Q3 2025 and troughed at $153000.0 in Q1 2025.
  • The 4-year median for Other Accumulated Expenses is $345500.0 (2025), against an average of $348250.0.
  • Year-over-year, Other Accumulated Expenses dropped 4.12% in 2024 and then soared 135.29% in 2026.
  • A 4-year view of Other Accumulated Expenses shows it stood at $291000.0 in 2023, then fell by 4.12% to $279000.0 in 2024, then soared by 47.31% to $411000.0 in 2025, then decreased by 12.41% to $360000.0 in 2026.
  • Per Business Quant, the three most recent readings for ADGM's Other Accumulated Expenses are $360000.0 (Q1 2026), $411000.0 (Q4 2025), and $513000.0 (Q3 2025).